Trials / Withdrawn
WithdrawnNCT00162500
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- Sponsor
- Hadassah Medical Organization · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Rationale: ImMucin was shown to be able to induce a robust cellular immune response mediated via both CD4+ and CD8+ T lymphocytes and therefore, could potentially be more effective in the majority of the target population. Purpose: The purpose of this study is to evaluate the safety and initial efficacy of ImMucin, a novel peptide vaccine in metastatic tumors expressing the MUC-1 Tumor Associated Antigen (TAA).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Peptide Vaccine (MUC-1) |
Timeline
- First posted
- 2005-09-13
- Last updated
- 2010-11-10
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00162500. Inclusion in this directory is not an endorsement.